Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
Open accessAbstract
BACKGROUND The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the pivotal phase 3 POISE trial. METHODS In the double-blind phase of POISE, 217 patients with primary biliary cholangitis with inadequate response to or intolerance to ursodeoxycholic acid were randomised to receive placebo, obeticholic acid 5 to 10 mg, or obeticholic acid 10 mg once daily for 12 months. During the open-label extension phase, patients received variable, adjusted doses of obeticholic acid. Markers of cholestasis and liver injury, alkaline phosphatase (ALP), and total and direct bilirubin were evaluated, and safety was assessed for up to 48 months of treatment with obeticholic acid. All analyses in the open-label extension were done in the safety population, defined as any patient randomised in the double-blind phase who received at least one dose of obeticholic acid during the open-label extension. This trial is registered at ClinicalTrials.gov (NCT01473524) and with EudraCT (2011-004728-36). FINDINGS 193 patients were treated during the open-label extension. In this 3-year interim analysis, ALP concentrations were significantly reduced compared with baseline at 12 months (mean change -105·2 U/L [SD 87·6]), 24 months (-101·0 U/L [98·5]), 36 months (-108·6 U/L [95·7]), and 48 months (-95·6 U/L [121·1]; p<0·0001 for all yearly time points). Total bilirubin concentrations were stabilised, with significant reductions versus baseline at 12 months (mean change -0·9 μmol/L [SD 4·1]; p=0·0042) and 48 months (-0·8 μmol/L [3·8]; p=0·016). Stabilisation was also noted for direct bilirubin, with a significant change from baseline at 12 months (mean change -0·5 μmol/L [SD 3·0]; p=0·021). However, changes in total and direct bilirubin were not significant at other time points. Obeticholic acid was generally well tolerated, with pruritus (149 [77%] patients) and fatigue (63 [33%]) being the most common adverse events. No serious adverse events were considered related to obeticholic acid. INTERPRETATION Interim analyses suggest long-term efficacy and safety of obeticholic acid in patients with primary biliary cholangitis who are intolerant to or inadequately responsive to ursodeoxycholic acid. FUNDING Intercept Pharmaceuticals.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · see citing works
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · see citing works
Self-citationSchwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241 · see citing works
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · see citing works
Self-citationLindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099 · see citing works
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · see citing works
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · see citing works
Phan, N. Q., Blome, C., Fritz, F., Gerss, J., Reich, A., Ebata, T., Augustin, M., Szepietowski, J. C., & Ständer, S. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1246 · Cited by 582 · see citing works
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576 · see citing works
Self-citationLammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498 · see citing works
Self-citationFiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472 · see citing works
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441 · see citing works
Self-citationCipriani, S., Mencarelli, A., Palladino, G., & Fiorucci, S. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m001602 · Cited by 410 · see citing works
Carbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386 · see citing works
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354 · see citing works
Self-citationA randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology · doi:10.1002/hep.29569 · Cited by 281 · see citing works
Self-citationHyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis
Longo, M., Crosignani, A., Battezzati, P. M., Squarcia Giussani, C., Invernizzi, P., Zuin, M., & Podda, M. (2002) · Gut · doi:10.1136/gut.51.2.265 · Cited by 190 · see citing works
FXR Regulates Liver Repair after CCl4-Induced Toxic Injury
Meng, Z., Wang, Y., Wang, L., Jin, W., Liu, N., Pan, H., Liu, L., Wagman, L. D., FORMAN, B. M., & Huang, W. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0286 · Cited by 113 · see citing works
Solaymani-Dodaran, M., Aithal, G. P., Card, T., & West, J. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02092.x · Cited by 65 · see citing works
New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
Jhaveri, M. A., & Kowdley, K. V. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s113052 · Cited by 44 · see citing works
Cash, W. J., McCance, D., Young, I., McEneny, J., Cadden, I., Mcdougall, N., & Callender, M. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00717.x · Cited by 31 · see citing works
Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.
Bahar, R., Wong, K. A., Liu, C. H., & Bowlus, C. L. (2018) · Europe PMC (PubMed Central) · Cited by 28 · see citing works
Self-citationCarbone, M., Harms, M. H., Lammers, W. J., Marmon, T., Pencek, R., MacConell, L., Shapiro, D., Jones, D. E., Mells, G. F., & Hansen, B. E. (2018) · Hepatology Communications · doi:10.1002/hep4.1180 · Cited by 26 · see citing works
Self-citationDoycheva, I. (2011) · World Journal of Hepatology · doi:10.4254/wjh.v3.i4.93 · Cited by 22 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850 · see citing works
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490 · see citing works
Self-citationMolecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481 · see citing works
Bile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 262 · see citing works
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253 · see citing works
Self-citationMetabolic Messengers: bile acids
Perino, A., & Schoonjans, K. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00559-z · Cited by 223 · see citing works
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · see citing works
Self-citationCurrent understanding of primary biliary cholangitis
Tanaka, A. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0028 · Cited by 159 · see citing works
Bile acids and their receptors: modulators and therapeutic targets in liver inflammation
Bertolini, A., Fiorotto, R., & Strazzabosco, M. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00935-7 · Cited by 142 · see citing works
Sanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.014 · Cited by 137 · see citing works
You, H., Ma, X., Efe, C., Wang, G., Jeong, S.-H., Abe, K., Duan, W., Chen, S., Kong, Y., Zhang, D., et al. (2022) · Hepatology International · doi:10.1007/s12072-021-10276-6 · Cited by 133 · see citing works
New Treatment Paradigms in Primary Biliary Cholangitis
Levy, C., Manns, M. P., & Hirschfield, G. M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.005 · Cited by 141 · see citing works
Self-citationObeticholic acid-a new therapy in PBC and NASH
Chapman, R. W., & Lynch, K. D. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa006 · Cited by 116 · see citing works
Current and potential treatments for primary biliary cholangitis
Shah, R. A., & Kowdley, K. V. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30343-7 · Cited by 115 · see citing works
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114 · see citing works
Self-citationMurillo Perez, C. F., Fisher, H., Hiu, S., Kareithi, D., Adekunle, F., Mayne, T., Malecha, E., Ness, E., van der Meer, A. J., Lammers, W. J., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.054 · Cited by 107 · see citing works
Self-citationReview article: therapeutic aspects of bile acid signalling in the gut‐liver axis
Simbrunner, B., Trauner, M. A., & Reiberger, T. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16602 · Cited by 107 · see citing works
Self-citationBowlus, C. L., Pockros, P. J., Kremer, A. E., Parés, A. R., Forman, L., Drenth, J. P. H., Ryder, S. D., Terracciano, L., Jin, Y., Liberman, A., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.09.050 · Cited by 105 · see citing works
Self-citationA Current Understanding of Bile Acids in Chronic Liver Disease
Farooqui, N., Elhence, A., & Shalimar, S. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.08.017 · Cited by 91 · see citing works
Recent advances on FXR-targeting therapeutics
Panzitt, K., Zollner, G., Marschall, H., & Wagner, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111678 · Cited by 87 · see citing works
Real-world experience with obeticholic acid in patients with primary biliary cholangitis
D’Amato, D., De Vincentis, A., Malinverno, F., Viganò, M., Alvaro, D., Pompili, M., Picciotto, A., Palitti, V. P., Russello, M., Storato, S., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100248 · Cited by 85 · see citing works
Vesterhus, M. N., & Karlsen, T. H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01681-z · Cited by 80 · see citing works
Soret, P., Lam, L., Carrat, F., Smets, L., Berg, T., Carbone, M., Invernizzi, P., Leroy, V., Trivedi, P., Cazzagon, N., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16336 · Cited by 78 · see citing works
Self-citationBile acid-mediated signaling in cholestatic liver diseases
Zeng, J., Fan, J., & Zhou, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01035-1 · Cited by 78 · see citing works
PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
Colapietro, F., Gershwin, M. E., & Lleò, A. (2023) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2023.100188 · Cited by 76 · see citing works
Kowdley, K. V., Hirschfield, G. M., Coombs, C., Malecha, E. S., Bessonova, L., Li, J., Rathnayaka, N. S., Mells, G. F., Jones, D. E., Trivedi, P. J., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003029 · Cited by 73 · see citing works
Self-citationCholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice
Cabrera-Rubio, R., Patterson, A. M., Cotter, P. D., & Beraza, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-48784-z · Cited by 61 · see citing works
Lemoinne, S., & Friedman, S. L. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.006 · Cited by 60 · see citing works
Park, J. W., Kim, J. H., Kim, S. E., Jung, J. H., Jang, M. K., Park, S. H., Lee, M. S., Kim, H. S., Suk, K. T., & Kim, D. J. (2022) · Biomedicines · doi:10.3390/biomedicines10061288 · Cited by 58 · see citing works
Schramm, C., Wedemeyer, H. H., Mason, A. L., Hirschfield, G. M., Levy, C., Kowdley, K. V., Milkiewicz, P., Janczewska, E., Malova, E. S., Sanni, J., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100544 · Cited by 53 · see citing works
Self-citationJohn, B. V., Schwartz, K., Levy, C., Dahman, B., Deng, Y., Martin, P., Taddei, T. H., & Kaplan, D. E. (2021) · Hepatology Communications · doi:10.1002/hep4.1720 · Cited by 51 · see citing works
Nevens, F., Trauner, M. A., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 51 · see citing works
Self-citationBile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma
Song, Y., Lau, H. C.-H., Zhang, X., & Yu, J. Q. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0394 · Cited by 50 · see citing works
The gut microbiota-bile acid axis in cholestatic liver disease
Sun, D.-Y., Xie, C., Zhao, Y., Liao, J.-M., Li, S.-S., Zhang, Y.-N., Wang, D.-D., Hua, K., Gu, Y.-C., Du, J.-B., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00830-x · Cited by 53 · see citing works
Prevention of First Decompensation in Advanced Chronic Liver Disease
Mandorfer, M., & Simbrunner, B. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.01.003 · Cited by 49 · see citing works
Alam, S., & Lal, B. B. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i1.98 · Cited by 47 · see citing works
Li, H. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.07.006 · Cited by 47 · see citing works
Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases
Almeqdadi, M., & Gordon, F. D. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.013 · Cited by 47 · see citing works
The history and future of bile acid therapies
Beuers, U. H., Bañales, J. M., Karpen, S. J., Keitel, V., Williamson, C., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.010 · Cited by 43 · see citing works
Self-citationRedox‐Dependent Effects in the Physiopathological Role of Bile Acids
Orozco-Aguilar, J., Simón, F., & Cabello‐Verrugio, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/4847941 · Cited by 43 · see citing works
Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders
Molinaro, A., & Marschall, H. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210658 · Cited by 43 · see citing works
UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis
Abbas, N., Culver, E. L., Thorburn, D., Halliday, N., Crothers, H., Dyson, J. K., Phaw, N. A., Aspinall, R., Khakoo, S. I., Kallis, Y. N., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.07.038 · Cited by 42 · see citing works
Self-citationObeticholic Acid for Primary Biliary Cholangitis
Floreani, A., Gabbia, D., & De Martin, S. (2022) · Biomedicines · doi:10.3390/biomedicines10102464 · Cited by 41 · see citing works
Gomez, E., Garcia Buey, L., Molina, E., Casado, M., Conde, I., Berenguer, M., Jorquera, F., Simón, M., Olveira, A., Hernández‐Guerra, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16181 · Cited by 41 · see citing works
Sohail, M. I., Çakıl, Y. D., Szöllősi, D., Stockner, T., & Chiba, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020784 · Cited by 39 · see citing works
Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17755 · Cited by 39 · see citing works
Self-citationDiagnosis and treatment of primary biliary cholangitis
Laschtowitz, A., de Veer, R. C., der Meer, A. J. V., & Schramm, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620919585 · Cited by 38 · see citing works
Montaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 40 · see citing works
Review article: pathophysiology and management of primary biliary cholangitis
Leung, K. K., Deeb, M., & Hirschfield, G. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16023 · Cited by 39 · see citing works
Self-citationEfficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis
Kulkarni, A. V., Tevethia, H. V., Arab, J. P., Cândia, R., Premkumar, M., Kumar, P., Sharma, M., Reddy, D. N., & Padaki, N. R. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101675 · Cited by 40 · see citing works
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 41 · see citing works
Yang, D., Wei, X., Zhang, Z., Chen, X., Zhu, R., Oh, Y., & Gu, N. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110027 · Cited by 37 · see citing works
Regulating bile acids signaling for NAFLD: molecular insights and novel therapeutic interventions
Wei, M., Tu, W., & Huang, G. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1341938 · Cited by 37 · see citing works
Reig, A., Álvarez‐Navascués, C., Vergara, M., Domínguez, E. G., Gallego, A., Pérez-Medrano, I., Fábrega, E., Hernández‐Guerra, M., Berenguer, M., Estévez, P., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001343 · Cited by 35 · see citing works
Self-citationLiu, Y., Liu, T., Zhao, X. M., & Gao, Y. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04509-6 · Cited by 34 · see citing works
MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets
Huang, C., Xing, X., Xiang, X., Fan, X., Men, R., Ye, T., & Yang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110558 · Cited by 32 · see citing works
Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
Kowdley, K., Bowlus, C., Levy, C., Mayo, M., Pratt, D., Vuppalanchi, R., & Younossi, Z. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002070 · Cited by 30 · see citing works
Self-citationFiorucci, S., Biagioli, M., Baldoni, M., Ricci, P., Sepe, V., Zampella, A., & Distrutti, E. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1916465 · Cited by 31 · see citing works
Vincentis, A. D., D’Amato, D., Cristoferi, L., Gerussi, A., Malinverno, F., Lleò, A., Colapietro, F., Marra, F., Galli, A., Fiorini, C., et al. (2022) · Liver International · doi:10.1111/liv.15386 · Cited by 30 · see citing works
PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
Hayes, C. M., Gallucci, G. M., Boyer, J. L., Assis, D. N., & Ghonem, N. S. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000612 · Cited by 30 · see citing works
New treatments/targets for primary biliary cholangitis
Corpechot, C., Poupon, R. Y., & Chazouillères, O. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.05.005 · Cited by 30 · see citing works
Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?
Yang, Y., He, X.-S., Rojas, M., Leung, P. S. C., & Gao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1184252 · Cited by 29 · see citing works
Chascsa, D. M. H., & Lindor, K. D. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01664-0 · Cited by 28 · see citing works
The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
Mazzetti, M., Marconi, G., Mancinelli, M., Benedetti, A., Marzioni, M., & Maroni, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081763 · Cited by 28 · see citing works
Overi, D., Carpino, G., Cristoferi, L., Onori, P., Kennedy, L. L., Francis, H., Zucchini, N., Rigamonti, C., Viganò, M., Floreani, A., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100556 · Cited by 28 · see citing works
Targeting NTCP for liver disease treatment: A promising strategy
Tan, X. H., Yu, X., Shi, J., Chen, L., & Yu, D. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.100979 · Cited by 27 · see citing works
Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021)
You, H., Duan, W., Li, S., Lv, T., Chen, S., Lu, L., Ma, X., Han, Y., Nan, Y., Xu, X., et al. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00347 · Cited by 29 · see citing works
18β-Glycyrrhetinic Acid Protects against Cholestatic Liver Injury in Bile Duct-Ligated Rats
Pan, P., Wang, Y., Lin, S., Liao, S., Chen, Y., Huang, W., Chen, C., & Chen, W. (2022) · Antioxidants · doi:10.3390/antiox11050961 · Cited by 26 · see citing works
Primary biliary cholangitis: treatment
Cazzagon, N., & Floreani, A. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000708 · Cited by 25 · see citing works
Bioactive Compounds from Brown Algae Alleviate Nonalcoholic Fatty Liver Disease: An Extensive Review
Wu, Y., Jin, X., Zhang, Y., Liu, J., Wu, M., & Tong, H. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06578 · Cited by 26 · see citing works
Pediatric Cholestasis: Epidemiology, Genetics, Diagnosis, and Current Management
Karpen, S. J. (2020) · Clinical Liver Disease · doi:10.1002/cld.895 · Cited by 24 · see citing works
Alvaro, D., Carpino, G., Craxı̀, A., Floreani, A., Moschetta, A., & Invernizzi, P. (2020) · Liver International · doi:10.1111/liv.14627 · Cited by 23 · see citing works
Lachiondo‐Ortega, S., Mercado-Gómez, M., Serrano‐Maciá, M., Lopitz‐Otsoa, F., SALAS-VILLALOBOS, T. B., Varela‐Rey, M., Delgado, T. C., & Martínez‐Chantar, M. L. (2019) · Cells · doi:10.3390/cells8121575 · Cited by 22 · see citing works
Widespread gaps in the quality of care for primary biliary cholangitis in UK
Sivakumar, M., Gandhi, A., Shakweh, E., Li, Y. M., Safinia, N., Smith, B. C., Marshall, A., Turner, L., Mukhopadhya, A., Haboubi, H., et al. (2021) · Frontline Gastroenterology · doi:10.1136/flgastro-2020-101713 · Cited by 21 · see citing works
Fuchs, C. D., SRODA, N., Scharnagl, H., Gupta, R. S., Minto, W. C., Stojaković, T., Liles, J. T., Budas, G. R., Hollenback, D., & Trauner, M. A. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100874 · Cited by 21 · see citing works
Self-citationBernts, L. H. P., Jones, D. E. J., Kaatee, M. M., Lohse, A. W., Schramm, C., Sturm, E., & Drenth, J. P. H. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1152-z · Cited by 21 · see citing works
Self-citationLevy, C., Trivedi, P. J., Kowdley, K. V., Gordon, S. C., Bowlus, C. L., Londoño, M. C., Hirschfield, G. M., Gulamhusein, A., Lawitz, E. J., Vierling, J. M., et al. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003603 · Cited by 20 · see citing works
Self-citationGerussi, A., D’Amato, D., Cristoferi, L., O’Donnell, S. E., Carbone, M., & Invernizzi, P. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.09.009 · Cited by 20 · see citing works
Parés, A. R., Shiffman, M. L., Vargas, V., Invernizzi, P., Malecha, E. S., Liberman, A., MacConell, L., & Hirschfield, G. M. (2020) · Liver International · doi:10.1111/liv.14429 · Cited by 19 · see citing works
Self-citationUpdate on the Pharmacological Treatment of Primary Biliary Cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2022) · Biomedicines · doi:10.3390/biomedicines10082033 · Cited by 19 · see citing works
Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy
Stoelinga, A., Biewenga, M., Drenth, J. P. H., Verhelst, X., van der Meer, A. J. P., de Boer, Y. S., Bouma, G., de Vries, E. S., Verdonk, R. C., van den Berg, A. P., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101088 · Cited by 20 · see citing works
Self-citationde Veer, R. C., van Hooff, M. C., Corpechot, C., Thorburn, D., Invernizzi, P., Lammers, W. J., Janssen, H. L. A., Battezzati, P. M., Nevens, F., Lindor, K. D., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002128 · Cited by 18 · see citing works
Self-citationPrimary biliary cholangitis and the narrowing gap towards optimal disease control
Cançado, G. G. L., Lleò, A., Levy, C., Trauner, M., & Hirschfield, G. M. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00025-1 · Cited by 19 · see citing works
Self-citationXu, C., Yue, R., Lv, X., Wang, S., & Du, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835991 · Cited by 16 · see citing works
Rapacciuolo, P., Finamore, C., Giorgio, C. D., Fiorillo, B., Massa, C., Urbani, G., Marchianò, S., Bordoni, M., Cassiano, C., Morretta, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01651 · Cited by 13 · see citing works
Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases
Saha, P., & Hartmann, P. (2025) · Microorganisms · doi:10.3390/microorganisms13061188 · Cited by 16 · see citing works
Hvistendahl, M., Naimi, R. M., Hansen, S. H., Rehfeld, J. F., Kissow, H., Pedersen, J., Dragsted, L. O., Sonne, D. P., Knop, F. K., & Jeppesen, P. B. (2021) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2224 · Cited by 15 · see citing works
Zhang, C., Gan, Y., Lv, J.-W., Qin, M.-Q., Hu, W., Liu, Z.-B., Ma, L., Song, B., Li, J., Jiang, W., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106442 · Cited by 15 · see citing works
Wetten, A., Jones, D. E. J., & Dyson, J. K. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2130750 · Cited by 14 · see citing works
Inflammation drives pathogenesis of early intestinal failure-associated liver disease
Fligor, S. C., Tsikis, S. T., Hirsch, T. I., Jain, A., Sun, L., Rockowitz, S., Gura, K. M., & Puder, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-54675-9 · Cited by 14 · see citing works
Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 14 · see citing works
Cançado, G. G. L., Couto, C. A., Terrabuio, D. R. B., Cançado, E. L. R., Villela‐Nogueira, C. A., Ferraz, M. L. G., Braga, M. H., Nardelli, M. J., Faria, L. C., Gomes, N. M. D. F., et al. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07654-x · Cited by 14 · see citing works
Saeedian, B., Babajani, N., Bagheri, T., Shirmard, F. O., & Pourfaraji, S. M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03821-2 · Cited by 14 · see citing works
Gene Therapy for Acquired and Genetic Cholestasis
Martínez-García, J., Molina, A., González‐Aseguinolaza, G., Weber, N. D., & Smerdou, C. (2022) · Biomedicines · doi:10.3390/biomedicines10061238 · Cited by 13 · see citing works
Yamashita, M., Honda, A., Shimoyama, S., Umemura, M., Ohta, K., Chida, T., Noritake, H., Kurono, N., Ichimura‐Shimizu, M., Tsuneyama, K., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103027 · Cited by 13 · see citing works
Vincentis, A. D., Ampuero, J., Terracciani, F., D’Amato, D., Gerussi, A., Cristoferi, L., Cazzagon, N., Bonaiuto, E., Floreani, A., Calvaruso, V., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.008 · Cited by 12 · see citing works
Zhao, D., Yan, H., Liao, H.-Y., Liu, Y., Han, Y., Zhang, H., Zhang, W.-M., Huang, C., Liu, X., Lou, J.-L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1098076 · Cited by 11 · see citing works
The treatment of primary biliary cholangitis: from shadow to light
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., & Jarčuška, P. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241265782 · Cited by 10 · see citing works
Komori, A., & Kugiyama, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0821 · Cited by 10 · see citing works
Obeticholic Acid—A Pharmacological and Clinical Review
Keshvani, C., Kopel, J. J., & Goyal, H. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010017 · Cited by 10 · see citing works
- Authors
- Trauner, M., Nevens, F., Shiffman, M. L., Drenth, J. P. H., Bowlus, C. L., Vargas, V., Andreone, P., Hirschfield, G. M., Pencek, R., Malecha, E. S., MacConell, L., & Shapiro, D.
- Affiliations
- Medical University of Vienna (AT)
- KU Leuven (BE)
- Bon Secours Liver Institute of Hampton Roads (US)
- Radboud University Medical Center (NL)
- University of California, Davis (US)
- National Institute for Health and Care Research (GB)
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Trauner, Michael
- ORCID
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 4
- Issue
- 6
- Pages
- 445-453
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W2922727372
- Semantic Scholar
- 0b165ee31de96a2d016dc69d19703615a5965f51
- Cited by
- 180
- References
- 24
- Citations by year
- 2026: 10 · 2025: 29 · 2024: 23 · 2023: 21 · 2022: 37 · 2021: 27 · 2020: 23 · 2019: 10
- FWCI
- 15.46
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- The Lancet. Gastroenterology & hepatology (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Intercept Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- obeticholic acid, primary biliary cirrhosis, long-term efficacy, drug safety, alkaline phosphatase, total bilirubin, direct bilirubin, cholestasis, liver injury, open-label extension, POISE trial, fumarate esters
- MeSH terms
- Alkaline Phosphatase, Bilirubin, Chenodeoxycholic Acid, Cholagogues and Choleretics, Cholangitis, Dose-Response Relationship, Drug, Double-Blind Method, Fatigue, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Pruritus, Ursodeoxycholic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
